Effect of montelukast (ML) of an additional therapy in steroid dependent children with asthma

T. V. Zaharov, S. S. Kamenov, V. V. Djordjevic, B. A. Kamenov (Pirot, Nis, Yugoslavia)

Source: Annual Congress 2003 - Evaluation of asthma therapy in children
Session: Evaluation of asthma therapy in children
Session type: Thematic Poster Session
Number: 878
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. V. Zaharov, S. S. Kamenov, V. V. Djordjevic, B. A. Kamenov (Pirot, Nis, Yugoslavia). Effect of montelukast (ML) of an additional therapy in steroid dependent children with asthma. Eur Respir J 2003; 22: Suppl. 45, 878

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 132s
Year: 2003

Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001

Anti-inflammatory effect of an additional therapy with Montelukast on steroid-dependent children with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 492s
Year: 2001

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review
Source: Annual Congress 2011 - Asthma management and response
Year: 2011


Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

Effect of 1 year treatment with inhaled corticosteroids with electronically assessed adherence on height growth in children with asthma
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


Meta-analysis of inhaled corticosteroids response in children with asthma.
Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics
Year: 2019


The effects of addition montelukast to inhaled steroids in the regular treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009


Effect of the leukotriene-receptor antagonists and interval hypoxic trainings (IHT) at children with asthma (BA) and allergic rhinitis (AR)
Source: Annual Congress 2008 - Exercise-induced asthma, acute severe asthma and allergic rhinitis in children
Year: 2008

Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015


Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016


Effect of long-acting ß-agonist on bronchodilator response in children with asthma
Source: Eur Respir J, 56 (3) 1902010; 10.1183/13993003.02010-2019
Year: 2020